Compare Stocks: CLNN, SBTX, DERM, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.89 -1.0%	$5.29	$1.00 ▼ $7.19	$222.27M	-0.99	220,075 shs	77,183 shs
CLNN Clene	$3.85 -3.5%	$5.15	$3.72 ▼ $13.50	$49.47M	0.95	96,670 shs	122,559 shs
DERM Journey Medical	$7.86 -0.5%	$6.95	$4.31 ▼ $9.56	$221.84M	1.09	213,047 shs	51,229 shs
SBTX Silverback Therapeutics	$5.62 -0.9%	$6.53	$2.80 ▼ $8.97	$211.66M	0.6	337,931 shs	852,847 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	+5.56%	-3.13%	+54.19%	+362.32%
CLNN Clene	0.00%	-8.98%	-27.90%	-29.36%	-31.13%
DERM Journey Medical	0.00%	+5.22%	+20.37%	+31.66%	+13.09%
SBTX Silverback Therapeutics	-0.88%	-4.58%	+4.85%	-34.35%	-49.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.89 -1.0%	$5.29	$1.00 ▼ $7.19	$222.27M	-0.99	220,075 shs	77,183 shs
CLNN Clene	$3.85 -3.5%	$5.15	$3.72 ▼ $13.50	$49.47M	0.95	96,670 shs	122,559 shs
DERM Journey Medical	$7.86 -0.5%	$6.95	$4.31 ▼ $9.56	$221.84M	1.09	213,047 shs	51,229 shs
SBTX Silverback Therapeutics	$5.62 -0.9%	$6.53	$2.80 ▼ $8.97	$211.66M	0.6	337,931 shs	852,847 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	+5.56%	-3.13%	+54.19%	+362.32%
CLNN Clene	0.00%	-8.98%	-27.90%	-29.36%	-31.13%
DERM Journey Medical	0.00%	+5.22%	+20.37%	+31.66%	+13.09%
SBTX Silverback Therapeutics	-0.88%	-4.58%	+4.85%	-34.35%	-49.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANTX Anthem	2.33	Hold	$9.00	52.80% Upside
CLNN Clene	2.71	Moderate Buy	$33.25	763.64% Upside
DERM Journey Medical	2.25	Hold	$14.00	78.12% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLNN, SBTX, DERM, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	ANTX Anthem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANTX Anthem	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CLNN Clene	$200K	247.36	N/A	N/A	($1.93) per share	-1.99
DERM Journey Medical	$61.86M	3.59	N/A	N/A	$1.14 per share	6.89
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
CLNN Clene	-$26.17M	-$3.50	N/A	N/A	N/A	-20,063.96%	N/A	-137.04%	11/12/2026 (Estimated)
DERM Journey Medical	-$11.43M	-$0.22	N/A	8.73	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A

Latest CLNN, SBTX, DERM, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CLNN Clene	-$0.3680	-$1.08	-$0.7120	-$1.08	$0.06 million	$0.09 million
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANTX Anthem	N/A	14.32	14.32
CLNN Clene	N/A	3.07	3.07
DERM Journey Medical	0.64	1.59	1.41
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANTX Anthem	90.47%
CLNN Clene	23.28%
DERM Journey Medical	7.25%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
ANTX Anthem	22.61%
CLNN Clene	28.30%
DERM Journey Medical	14.53%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
CLNN Clene	100	12.85 million	9.21 million	No Data
DERM Journey Medical	90	28.22 million	24.12 million	N/A
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

CLNN, SBTX, DERM, and ANTX Headlines

Recent News About These Companies

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.orgP

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.comN

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.comP

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.ukW

A look back at RNA Therapeutics – day one

February 23, 2023 | pharmaphorum.comP

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.comT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.comK

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.comA

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.comB

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

September 6, 2022 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SBTX, DERM, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

$5.89 -0.06 (-1.01%)

As of 09/4/2026 04:00 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Clene NASDAQ:CLNN

$3.85 -0.14 (-3.51%)

As of 09/4/2026 04:00 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Journey Medical NASDAQ:DERM

$7.86 -0.04 (-0.51%)

As of 09/4/2026 04:00 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Silverback Therapeutics NASDAQ:SBTX

$5.62 -0.05 (-0.88%)

As of 09/4/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLNN, SBTX, DERM, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLNN, SBTX, DERM, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLNN, SBTX, DERM, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SBTX, DERM, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

Clene NASDAQ:CLNN

Journey Medical NASDAQ:DERM

Silverback Therapeutics NASDAQ:SBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLNN, SBTX, DERM, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLNN, SBTX, DERM, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLNN, SBTX, DERM, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SBTX, DERM, and ANTX Company Descriptions

Anthem NASDAQ:ANTX

Clene NASDAQ:CLNN

Journey Medical NASDAQ:DERM

Silverback Therapeutics NASDAQ:SBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools